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Hypophosphatasia (HPP) is a rare, poten-
tially life-threatening disease characterised
by hypomineralisation of bones and teeth.1
The fundamental defect is reduced func-
tional activity of the enzyme tissue-non-
speciﬁc alkaline phosphatase (usually just
termed alkaline phosphatase [ALP] in clin-
ical practice). Homozygous or compound
heterozygous mutations in the ALPL gene
result in the most severe phenotypes of HPP.
However, dominant negative effects can
also be observed when a single heterozygous
mutation affects the binding site(s) of the
ALP homodimer. ALP catabolises inorganic
pyrophosphate (PPi), an inhibitor of bone
mineralisation, and pyridoxal 50-phosphate
(PLP; major form of vitamin B6), allowing
pyridoxal to cross the blood–brain barrier
and enter pathways leading to neurotrans-
mitter synthesis.
There are six clinical forms of HPP,
four of which have clear relevance in
paediatric practice—perinatal, benign pre-
natal, infantile and juvenile HPP. In some
instances the adult form has unrecognised
paediatric onset, while odonto-HPP
simply affects the teeth.1 Bone-targeted
enzyme-replacement therapy (ERT) with
asfotase alfa (administered subcutaneously
3–6 times per week) is now available,
having recently been approved in several
regions. For those presenting early in life,
such treatment has been shown to reduce
mortality during the ﬁrst year of life from
∼97% in perinatally presenting cases and
close to 60% in cases presenting later in
infancy to ∼10% overall.
In contrast to many other disorders
treated with ERT, there is no accumula-
tion of toxic metabolites. Thus, with ERT,
many of the ﬁndings of HPP may be
reversible. Nonetheless, many patients
with perinatal-onset and infantile-onset
HPP are critically ill. Even with ERT,
improvements in bone mineralisation may
take weeks to months. In this regard,
some affected infants require considerable
periods of critical care support due to
respiratory compromise before demon-
strating marked clinical improvement.
Such compromise reﬂects the mechanical
inadequacy of gracile, poorly mineralised
ribs that may have fractured, and in some
instances, tracheobronchomalacia. In one
case study, a patient diagnosed in utero as
having perinatal lethal HPP demonstrated
severe hypomineralisation and required
immediate intensive respiratory care upon
birth. Radiographic improvements were
observed in rib mineralisation after
20 days of ERT, and by day 207 the
patient was fully weaned from mechanical
ventilation.2 These observations are sup-
ported by results from a recently pub-
lished study in which continuous ERT
resulted in improvements in bone mineral-
isation and respiratory outcomes, such
that of the 76% of the children who
required ventilatory support at baseline
and survived, 75% could be weaned from
this support.3 Some infants suffer convul-
sions due to lack of pyridoxine getting
across the blood–brain barrier. Survival in
infants who suffered convulsions and
were treated with ERT was 77%, com-
pared with a 100% mortality rate in a set
of historical control infants who were not
treated.3
Raised intracranial pressure can arise
secondary to craniosynostosis, which is
common in those presenting early in life.
Frequent monitoring of head circumfer-
ence and inspection of the optic discs
should be undertaken. In affected infants,
gross and ﬁne motor functions are
delayed but show steady catch-up over
time; cognitive function is usually within
the normal range within 12 months of
starting treatment. A benign prenatal
form of HPP has been classiﬁed that is
typically diagnosed on ultrasound ante-
natally and may show signiﬁcant spontan-
eous improvement postnatally. However,
this cannot be easily predicted, and the
postnatal course and severity of ‘benign
prenatal’ HPP ranges from that observed
in patients with infantile HPP to
odonto-HPP.4
While early tooth loss (due to failure of
normal cementum production) is a well-
recognised presentation in less severely
affected older children, the effect of HPP
on motor function is less recognised but
in some cases debilitating. Similarly, ado-
lescents and young adults can suffer
severe loss of their secondary dentition
and some may develop stress fractures,
particularly of metatarsals, that heal
slowly and lead to progressive loss of
mobility.
Because HPP presentation is so variable,
patients can present initially to different
healthcare specialists (eg, obstetrician/neo-
natologist, paediatrician, dentist, general
practitioner, orthopaedic surgeon),
making recognition of the clinical symp-
toms essential for rapid diagnosis and
access to treatment. We have developed a
diagnostic pathway to enable recognition
of symptoms and minimise misdiagnosis
(ﬁgure 1).
Clinical ﬁndings of the most common
manifestations are shown in ﬁgure 1;
note that presentation can be multisyste-
mic. Low ALP activity level is the hall-
mark of HPP and should be assessed
when HPP is suspected. Measurement of
ALP is easy to perform, readily available
and can lead to rapid diagnosis.
However, its interpretation requires
some care. The normal range for ALP is
age- and gender-speciﬁc, emphasising
the need for appropriate laboratory ref-
erence ranges.5 Some laboratories only
have one broad reference range for all
ages; physicians should be wary because
ALP levels that are normal for adults
could represent pathological levels for
children. Furthermore, there is often a
focus upon elevated ALP for the diagno-
sis of rickets/osteomalacia, rather than
low ALP levels.6
Together with low ALP levels, typical
radiological features of perinatal, infantile
and childhood HPP can conﬁrm the diag-
nosis. However, the radiological features
in mild childhood, adult and odonto-HPP
are not always diagnostic. Where the diag-
nosis is in doubt, conﬁrmatory laboratory
testing can include PLP, PPi or urinary
phosphoethanolamine levels, which are
usually above the reference range in
patients with HPP,5 6 as well as ALPL
mutational analyses.
The presence of any clinical ﬁndings
shown in ﬁgure 1 with a combination of
low ALP activity level should result in a
working diagnosis of HPP until proven
otherwise. Timely access to care and treat-
ment options is dependent on the critical
period between symptom onset and diag-
nosis. This is especially important for
patients with perinatal and infantile HPP,
where delays may have fatal conse-
quences, or in older patients where
1Department of Human Metabolism, University of
Shefﬁeld, Shefﬁeld, UK; 2Department of Endocrinology,
The Children’s Hospital at Westmead, Westmead, New
South Wales, Australia; 3Department of Paediatrics and
Child Health, University of Sydney, Sydney, New South
Wales, Australia; 4Department of Pediatrics, Osaka
University, Graduate School of Medicine, Suita, Osaka,
Japan
Correspondence to Dr Nick Bishop, Department of
Human Metabolism, University of Shefﬁeld, Shefﬁeld
S10 2TH, UK; n.j.bishop@shefﬁeld.ac.uk
514 Bishop N, et al. Arch Dis Child June 2016 Vol 101 No 6
Leading article
treatment with bisphosphonates may
worsen the bone phenotype. Improving
awareness will increase the likelihood of a
correct diagnosis and minimise the period
between symptom onset and initiating the
newly available, potentially life-saving
therapy.
We hope that despite the inconveni-
ence of frequent injections and the high
cost of the treatment, this transforma-
tive therapy will be implemented for
those in whom HPP is currently
life-limiting.
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Figure 1 Hypophosphatasia (HPP) diagnostic pathway. This pathway focuses on presentation and diagnosis of infants and children with HPP.
*Radiological ﬁndings can include profound hypomineralisation, irregularity of the provisional zone of calciﬁcation, physeal widening, metaphyseal
ﬂaring/fraying, metaphyseal radiolucencies and fractures.1 3 ALP, alkaline phosphatase; PEA, phosphoethanolamine; PLP, pyridoxal 50-phosphate;
PPi, inorganic pyrophosphate.
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